

# 3rd DAY CONFERENCE

## LIQUID BIOPSY:

Latest advances and applications in oncology  
Hybrid event

Friday,  
4<sup>th</sup> October,  
2024

10:00-18:30

Kostis  
Palamas  
building  
NKUA

Hellenic Society of Liquid Biopsy  
<https://hsliquidbiopsy.wixsite.com/2024>

### Hellenic Society of Liquid Biopsy

«LIQUID BIOPSY: Latest advances and applications in oncology»

Friday 4<sup>th</sup> October 2024

Kostis Palamas building, NKUA

#### PROGRAM

9.00-10.00	Registration	
Chairing: E. Lianidou, A. Markou		
10.00 – 10.30	Liquid Biopsy: latest advancements	Evi Lianidou
10.30 – 11.00	Liquid Biopsy: An update on the latest technology advancements	Athina Markou
11.00 – 11.30	Quality Control and standardization in Liquid Biopsies: How important is it??	Aliki Ntzifa
11.30 – 12.00	Harnessing liquid biopsy assays to deliver precision medicine in head and neck cancer	Chamindie Punyadeera, Griffith University, Brisbane, Australia
12.00 – 12.30	“Utility of ctDNA analyses in the molecular tumour board”	Ellen Heitzer, Medical University of Graz, Austria
12.30 – 13.30	Lunch break	
Chairing: E. Lianidou, G. Kalergi CTCs		
13.30 – 14.00	CTC and biology of metastasis	Galatea Kalergi, University of Patras, Greece
14.00 – 14.30	PD-L1 in CTCs and immunotherapy response	Areti Strati, ACTC lab, NKUA, Greece
14.30 – 15.00	Liquid biopsy multi-analyte approach to monitor treatment resistance in prostate cancer	Amin El-Heliebi, Medical University of Graz, Austria
15.00 – 15.30	“Analyzing metastatic phenotypes and CTC clustering mechanisms using TetherChip microfluidics.”	Stuart S. Martin, University of Maryland School of Medicine, Baltimore, USA
15.30-16.00	Coffee break	

**Chairing: Ellen Heitzer, Evi Lianidou  
ctDNA analysis**

<b>16.00 –16.30</b>	<b>Novel liquid biopsy technologies for earlier detection of cancer and minimal residual disease</b>	<b>Mike Makrigiorgos, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA</b>
<b>16.30 – 17.00</b>	<b>“Liquid biopsy approaches for minimal residual disease detection and therapy response monitoring”</b>	<b>Valsamo Anagnostou, Johns Hopkins University School of Medicine, USA</b>
<b>17.00-17.30</b>	<b>“ctDNA based detection of MRD in colorectal cancer”</b>	<b>Claus Lindbjerg Andersen, Aarhus University, Denmark</b>
<b>17.30 – 18.00</b>	<b>ctDNA in early breast cancer challenges and opportunities</b>	<b>Michail Ignatiadis, Institut Bordet, Université Libre de Bruxelles, Belgium</b>
<b>18.00-18.30</b>	<b>Conclusions - Discussion</b>	